

8^a ACTUALIZACIÓN
EN EL TRATAMIENTO
DE LA **LEUCEMIA**
AGUDA

SPONSORS

PLATINUM



Jazz Pharmaceuticals



NOVARTIS

GOLD

abbvie



Daiichi-Sankyo



Janssen
PHARMACEUTICAL COMPANIES OF
Johnson & Johnson

SILVER

AMGEN



GILEAD



Pfizer



Roche

In collaboration with Astellas Pharma

ORGANIZED BY

MD Anderson
Cancer Center
Madrid • España

VENUE

RAFAEL DEL PINO
C/ Rafael Calvo 39
28010 Madrid

CREDITS

Continuing Education Credits requested to the Spanish National Health System

TECHNICAL SECRETARIAT

doctaforum
MEDICAL EVENTS SPECIALISTS

Monasterios de Suso y Yuso 34 • 28049 Madrid
(+34) 91 372 02 03
cursoleucemia@doctaforum.com
www.doctaforum.org/2019/cursoleucemia2019

8^a ACTUALIZACIÓN
EN EL TRATAMIENTO
DE LA **LEUCEMIA**
AGUDA

MADRID OCTOBER 04th • 05th 2019

COORDINATORS

Dr. Adolfo de la Fuente
MD Anderson Cancer Center Madrid, España

Dr. Miguel Ángel Sanz
Hospital Universitario y Politécnico La Fe, Valencia, España

MD Anderson
Cancer Center
Madrid • España

FRIDAY, 4th OCTOBER 2019

09:00 - 09:10 **Welcome**

09:10 - 10:25 **SESSION 1 - High risk AML symposium**

Chair: Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, España

09:10 - 09:30 **High Risk AML characteristics and biology**
Dr. Carolina Martínez Laperche, Hospital General Universitario Gregorio Marañón. Madrid, España

09:30 - 09:50 **Management of secondary AML, an aggressive approach**
Dr. Jeffrey E. Lancet, Moffitt Cancer Center. Tampa, EEUU

09:50 - 10:10 **Intensive chemotherapy in myelodisplastic syndromes**
Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, EEUU

10:10 - 10:25 **Discussion**

10:25 - 10:55 **Coffee Break**

10:55 - 11:50 **SESSION 2 - Diagnosis and monitoring of AML**

Chair: Dr. Miguel Ángel Sanz, Hospital Universitario y Politécnico La Fe. Valencia, España

10:55 - 11:15 **Targeting epigenetic mechanisms**
Dr. Alba Maiques-Díaz, IDIBAPS. Barcelona, España

11:15 - 11:35 **Hereditary myeloid neoplasms**
Dr. José Cervera, Hospital Universitario y Politécnico La Fe. Valencia, España

11:35 - 11:50 **Discussion**

11:50 - 13:05 **SESSION 3 - Lymphoblastic Leukemia**

Chairs: Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, España
Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, EEUU

11:50 - 12:10 **Master pathways in B-ALL: PETHEMA**
Dr. Josep-Maria Ribera, ICO-Hospital Universitari Germans Trias i Pujol.
Josep Carreras Research Institute. Badalona, España

12:10 - 12:30 **Tailored induction therapy in ALL**
Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, EEUU

12:30 - 12:50 **CAR-T in ALL**
Dr. Claudia Rössig, Universit of Münster NRW, Germany

12:50 - 13:05 **Discussion**

13:05 - 14:00 **SESSION 4 - Myeloid malignancies symposium**

Chairs: Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, EEUU
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, España

13:05 - 13:25 **Improving outcomes in low risk MDS**
Dr. Pierre Fenaux, Hôpital Avicenne. Paris, France

13:25 - 13:45 **Managing myelophibrosis after Ruxolitinib failure**
Dr. Valentín García Gutiérrez, Hospital Universitario Ramón y Cajal. Madrid, España

13:45 - 14:00 **Discussion**

14:00 - 16:00 **Lunch**

16:00 - 17:55 **SESSION 5 - Advances in the Treatment of AML**

Chair: Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, España

16:00 - 16:20 **Risk stratification for myeloid malignancies**
Dr. Miguel Ángel Sanz, Hospital Universitario y Politécnico La Fe. Valencia, España

16:20 - 16:40 **Immunotherapy in AML**
Dr. Naval Daver, MD Anderson Cancer Center, Houston, EEUU

16:40 - 17:00 **Targeting IDH**
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, España

17:00 - 17:20 **Targeting bone marrow inflammation with regulatory T cells**
Dr. Simrit Parmar, MD Anderson Cancer Center, Houston, EEUU

17:20 - 17:40 **The role of maintenance with FLT3 inhibitors**
Dr. Jorge Sierra, Hospital de la Santa Creu i Sant Pau. Barcelona, España

17:40 - 17:55 **Discussion**

17:55 - 19:10 **SESSION 6 - Symposium Targeting Apoptosis**

Chairs: Dr. Miguel Ángel Sanz, Hospital Universitario y Politécnico La Fe. Valencia, España
Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, EEUU

17:55 - 18:15 **Molecular point of view and dysregulation**
Dr. Joaquín Sánchez, Hospital Universitario Reina Sofia. Córdoba, España

18:15 - 18:35 **Targeting Bcl2 and MCL1**
Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, EEUU

18:35 - 18:55 **Targeting apoptosis in Melodisplastic sindromes**
Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, EEUU

18:55 - 19:10 **Discussion**

SATURDAY, 5th OCTOBER 2019

09:30 - 11:10 **Clinical Case Reviews: Acute Leukemias**

Unusual cases and rare leukemias

Chairs: Dr. Mayte Olave, Hospital Clínico Universitario Lozano Blesa. Zaragoza, España
Dr. Josefina Serrano, Hospital Universitario Reina Sofia. Córdoba, España

Expert: Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, EEUU

11:10 - 11:40 **Coffee Break**

11:40 - 12:55 **SESSION 7 - AML FLT3 Positive Symposium**

Chairs: Dr. Miguel Ángel Sanz, Hospital Universitario y Politécnico La Fe. Valencia, España
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, España

11:40 - 12:00 **The role of FLT3 inhibitors in induction therapy**
Dr. Marina Díaz Beyá, Hospital Clínic. Barcelona, Spain

12:00 - 12:20 **The role of maintenance with FLT3 inhibitors**
Dr. Jorge Sierra, Hospital de la Santa Creu i Sant Pau. Barcelona, España

12:20 - 12:40 **Targeting FLT3 in salvage therapy**
Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe. Valencia, España

12:40 - 12:55 **Discussion**

12:55 - 14:10 **SESSION 8 - Management in the Daily Practice of the AML FLT3+**

Chairs: Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, España
Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe. Valencia, España

12:55 - 13:15 **FLT3 Induction therapy in Spain**
Dr. Mar Tormo, Hospital Clínico Universitario de Valencia, España

13:15 - 13:35 **FLT3 positive AML in USA**
Dr. Naval Daver, MD Anderson Cancer Center, Houston, EEUU

13:35 - 13:55 **FLT3 positive AML in Italy**
Dr. Alessandro Isidori, Hematology and Stem Cell Transplant Center AORMN Hospital. Pesaro, Italy

13:55 - 14:10 **Discussion**

14:10 **Closing**